QURE

uniQure N.V.

Nasdaq Global Select

$18.64

Open: $18.99 High: $19.08 Low: $18.53 Close: $18.79

Range: 2022-06-27 - 2022-06-28

Volume:202,201

Market: Open

Get Free API Key

Download as Excel

QURE

uniQure N.V. PAASHEUVELWEG 25A https://www.uniqure.com

uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

CEO: Matthew C. Kapusta
Employees: 463
Sector: Healthcare
Industry: Biotechnology

Latest Stocks Posts

View All Posts >

QURE News

Latest news about the QURE

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! We're almost done with the week but we still need to go over the biggest pre-market stock movers for Friday!
by Investor Place at 3/4/22, 12:00 AMView More →
Biogen's experimental eye treatment fails to meet study goal
Biogen Inc's gene therapy for an inherited retinal disease that leads to progressive vision loss did not meet the main goal of a study, a development that increases focus on an upcoming decision on its under-review Alzheimer's drug.
by Reuters at 5/14/21, 3:25 PMView More →
BRIEF-CSL To Buy Late-Stage Gene Therapy Candidate For Haemophilia B From Uniqure
* ACQUIRE LATE-STAGE GENE THERAPY CANDIDATE FOR HAEMOPHILIA B FROM UNIQURE
by Reuters at 6/24/20, 10:46 PMView More →
BRIEF-Uniqure Announces License Agreement With CSL Behring To Commercialize Hemophilia B Gene Therapy
* UNIQURE ANNOUNCES LICENSE AGREEMENT WITH CSL BEHRING TO COMMERCIALIZE HEMOPHILIA B GENE THERAPY
by Reuters at 6/24/20, 8:12 PMView More →
BRIEF-Uniqure Says First Two Patients Treated In Phase I/II Clinical Trial Of AMT-130
* UNIQURE ANNOUNCES FIRST TWO PATIENTS TREATED IN PHASE I/II CLINICAL TRIAL OF AMT-130 FOR THE TREATMENT OF HUNTINGTON’S DISEASE
by Reuters at 6/19/20, 11:31 AMView More →
BRIEF-Uniqure Announces The Appointment Of Leonard E. Post, Ph.D. To Its Board Of Directors
* UNIQURE ANNOUNCES THE APPOINTMENT OF LEONARD E. POST, PH.D. TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:
by Reuters at 6/17/20, 8:19 PMView More →
7 Stocks to Buy With Over 20% Upside From Current Levels
As stocks keep pushing to highs again and again, where can you find smart stocks to buy right now? Check out these 7 excellent options.
by Investor Place at 7/30/19, 12:00 AMView More →
3 Top Gene Therapy Stocks That Could Soar
Biotech stocks targeting gene therapy are going to be huge. Here are 3 gene therapy stocks to buy that have a ton of potential.
by Investor Place at 5/30/19, 12:00 AMView More →
Play The Future of Gene Therapy With These 5 Biotech Stocks
What's the next big thing in biotech? The answer is gene therapy and these five biotech stocks are leading the way.
by Investor Place at 8/27/18, 12:00 AMView More →
7 Triple-A Stocks to Buy -- With 100% Street Support
These 7 'Strong Buy' stocks all have 100 % buy ratings from the Street. We use our big data capabilities to track the latest ratings from over 4,700 analysts. Here we delve down into why the Street is so bullish on our 7 top stocks to buy ideas.
by Investor Place at 5/22/18, 12:00 AMView More →

S&P 500

NASDAQ 100

FTSE 100

QQQ

TESLA

BTC/USD

GBP/USD

GOLD